Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib

Abstract

Our in vitro and in vivo results provide a new understanding of EphA2 targeting by dasatinib and identify key predictors of therapeutic response. These findings have implications for ongoing dasatinib-based clinical trials.